Alice Lee
Montefiore Medical Center · Montefiore Medical Center/Albert Einstein College of Medicine · Children's Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alice Lee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:53 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06892678 · DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or OsteosarcomaMontefiore Medical Center · recruiting · Osteosarcoma Recurrent, Ewing's Tumor Recurrent · principal investigator
- N/ANCT06384404 · Upfront Surgical Resection for OsteosarcomaMontefiore Medical Center · recruiting · Osteosarcoma · principal investigator
- Ph2NCT06233903 · 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous SystemInnervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · withdrawn · Neuroblastoma, Pheochromocytoma, Paraganglioma · principal investigator
- Ph2NCT03210714 · Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cell Identity Determination in Human Brain: Somatic Mutation and Cell LineageR01NS032457 · NINDS · BOSTON CHILDREN'S HOSPITAL · fiscal years 2025 to 2026 · $699,949 awarded in 2026Same name and institution; not confirmed by an ID
- Detection and Characterization of Somatic Mutations in Human Tissue Utilizing Duplex-Consensus SequencingUH3NS132144 · NINDS · BOSTON CHILDREN'S HOSPITAL · fiscal years 2025 to 2026 · $711,998 awarded in 2026Same name and institution; not confirmed by an ID
- Molecular and genomic basis of transposon-associated alternative splicingR01CA312218 · NCI · BOSTON CHILDREN'S HOSPITAL · fiscal years 2026 · $738,698 awarded in 2026Same name and institution; not confirmed by an ID
- Role of transposon dysregulation in Alzheimer and aging brains revealed by single-cell genomic and transcriptomic analysisR01AG078929 · NIA · BOSTON CHILDREN'S HOSPITAL · fiscal years 2022 to 2026 · $842,835 awarded in 2026Same name and institution; not confirmed by an ID
- Rates and mechanisms of age-related somatic mutation in normal and Alzheimer brainR01AG070921 · NIA · BOSTON CHILDREN'S HOSPITAL · fiscal years 2021 to 2025 · $809,811 awarded in 2025Same name and institution; not confirmed by an ID
- Detection and Characterization of Somatic Mutations in Human Tissue Utilizing Duplex-Consensus SequencingUG3NS132144 · NINDS · BOSTON CHILDREN'S HOSPITAL · fiscal years 2023 to 2024 · $434,514 awarded in 2024Same name and institution; not confirmed by an ID
- Role of clonal somatic mutations in microglia activation and Alzheimer’s diseaseR56AG079857 · NIA · BOSTON CHILDREN'S HOSPITAL · fiscal years 2023 · $883,191 awarded in 2023Same name and institution; not confirmed by an ID
- Mechanism for endogenous retroelements to mimic ancient exogenous identities in aging and diseased human tissueDP2AG072437 · NIA · BOSTON CHILDREN'S HOSPITAL · fiscal years 2020 · $2,655,000 awarded in 2020Same name and institution; not confirmed by an ID
- The role of somatic mutation in neurodegenerative diseaseK01AG051791 · NIA · BOSTON CHILDREN'S HOSPITAL · fiscal years 2016 to 2020 · $130,950 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- COG NCTN Network Group Operations CenterU10CA180886 · NCI · COG RESEARCH FOUNDATION, LLC · PI Douglas S. Hawkins · fiscal years 2014 to 2026Named on NCT03210714
- Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumorsUM1CA081457 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Ira J Dunkel, Arzu Onar-Thomas · fiscal years 2014 to 2026Named on NCT03210714
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:53 UTC. The ranking covers the 200 most relevant of 825 PubMed records, and a shared surname and initials can bring in a namesake. All 825 on PubMed
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med · 20183,177 citationsRCR 109.0
- 1,171 citationsRCR 43.0
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.Lancet Respir Med · 2019824 citationsRCR 28.8
- 781 citationsRCR 126.2
- Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.N Engl J Med · 2019678 citationsRCR 31.6
- Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial.Circulation · 2020334 citationsRCR 15.6
- Home-based rehabilitation for COPD using minimal resources: a randomised, controlled equivalence trial.Thorax · 2017314 citationsRCR 17.9
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.J Thorac Oncol · 2022285 citationsRCR 17.2
- Lasofoxifene in postmenopausal women with osteoporosis.N Engl J Med · 2010281 citationsRCR 7.5
- Screening for Occult Cancer in Unprovoked Venous Thromboembolism.N Engl J Med · 2015227 citationsRCR 8.7